For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
11
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
2 collections
    0
    shares
      746
      similar
       All similar

      Call for Papers: Digital Diagnostic Techniques

      Submit here before November 30, 2024

      About Pathobiology: 3.5 Impact Factor I 8.5 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cushing’s Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cushing’s syndrome (CS), secondary to paraneoplastic syndrome, is more commonly seen in small cell lung cancer but never before reported in epidermal growth factor receptor-mutated adenocarcinoma of the lung. Here, we present a case of a patient whose symptoms of hypokalemia, hypertension, and progressive abnormal glucose levels led to further workup that revealed adrenocorticotropic hormone-dependent hypercortisolism. Her cortisol levels dropped after 1 month of osilodrostat treatment, while lung cancer was treated with osimertinib. The use of osilodrostat in paraneoplastic CS has been previously reported in only 3 patients.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: not found

          Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

          Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste … (2018)
          Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC).
          Article 0 comments Cited 1567 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

            Yi-Long Wu, Masahiro Tsuboi, Jie He … (2020)
            Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown.
            Article 0 comments Cited 602 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

              Ramaswamy Govindan, Jay Piccirillo, Daniel Morgensztern … (2006)
              Small-cell lung cancer (SCLC) is a histologic subtype of lung cancer with a distinct biology and clinical course. It has been observed that the incidence of SCLC has been decreasing over the last several years. We used the Surveillance, Epidemiologic, and End Results (SEER) database to determine the incidence of SCLC over the last 30 years. In addition, we sought to determine sex- and stage-based differences in the incidence and survival of SCLC among a proportion of reported cases of lung cancer over the last 30 years (1973 to 2002). Joinpoint analyses were applied to test the trends in annual percentage change for statistical significance. The proportion of SCLC (among all lung cancer histologic types) decreased from 17.26% in 1986 to 12.95% in 2002. Of all patients with SCLC, the proportion of women with SCLC increased from 28% in 1973% to 50% in 2002. A modest but statistically significant improvement in 2- and 5-year survival was noted among both limited-stage SCLC and extensive-stage SCLC cohorts during the study period. Our analysis indicates that the incidence of SCLC is decreasing in the United States, and only modest improvements have been seen in survival over the last 30 years. Possible explanations for the decreasing incidence include the decrease in the percentage of smokers and the change to low-tar filter cigarettes. Despite trends toward modest improvement in survival, the outcome remains very poor.
              Article 0 comments Cited 262 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Case Rep Oncol
                Journal ID (iso-abbrev): Case Rep Oncol
                Journal ID (hwp): CRO
                Journal ID (publisher-id): CRO
                Title: Case Reports in Oncology
                Publisher: S. Karger AG (Basel, Switzerland )
                ISSN (Electronic): 1662-6575
                Publication date (Electronic): 1 March 2023
                Publication date Collection: Jan-Dec 2023
                Publication date PMC-release: 1 March 2023
                Volume: 16
                Issue: 1
                Pages: 124-128
                Affiliations
                [a ]MercyOne North Iowa Medical Center, Mason City, IA, USA
                [b ]Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
                Author notes
                Correspondence to: Young Kwang Chae, young.chae@ 123456northwestern.edu
                Article
                Publisher ID: 527824
                DOI: 10.1159/000527824
                PMC ID: 9978924
                PubMed ID: 36876215
                SO-VID: e0d30f75-2512-4e9a-93de-c7977533a963
                Copyright © © 2023 The Author(s). Published by S. Karger AG, Basel
                License:

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                Date received : 24 May 2022
                Date accepted : 10 October 2022
                Date: 2023
                Page count
                Figures: 3, References: 11, Pages: 5
                Funding
                This research received no external funding from funding agencies in the public, commercial, or not-for-profit sectors.
                Categories
                Subject: Case Report

                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: osilodrostat,ectopic adrenocorticotropic hormone-dependent cushing,epidermal growth factor receptor,case report
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: osilodrostat, ectopic adrenocorticotropic hormone-dependent cushing, epidermal growth factor receptor, case report

                Comments

                Comment on this article

                scite_

                Similar content746

                See all similar

                Cited by1

                See all cited by

                Most referenced authors227

                See all reference authors